5-Amino-1MQ Bloodwork: 8 Labs to Track (2026)
Most people track weight and energy — but the lab that actually shows if 5-amino-1MQ is working gets overlooked by 90% of users. HOMA-IR reveals metabolic improvements weeks before the scale budges, making it your early success indicator.
5-Amino-1MQ works by inhibiting NNMT (nicotinamide N-methyltransferase), which preserves cellular NAD+ and improves metabolic function. Unlike appetite suppressants, its benefits show up in bloodwork before becoming visible, making lab monitoring essential for tracking progress.
Biomarkers at a Glance
Click any bar to jump to the full breakdown.
Baseline Labs: Pre-Treatment Assessment
Before starting 5-amino-1MQ, establish baseline values for safety and efficacy tracking. These labs create your personal reference point and help identify contraindications.
Essential Pre-Treatment Panel:
- Comprehensive Metabolic Panel (liver and kidney function)
- Lipid panel (cholesterol, triglycerides)
- Fasting insulin and glucose
- HbA1c (3-month glucose average)
Safety Screening:
- Complete Blood Count (CBC)
- Thyroid function (TSH, free T3/T4)
- Inflammatory markers (if indicated)
Schedule baseline labs 1-2 weeks before starting treatment to ensure accurate pre-treatment values.
Why It Matters: NNMT inhibition directly affects lipid metabolism by preserving NAD+ cofactors essential for fat oxidation. Research consistently shows improvements in cholesterol and triglycerides with effective NNMT inhibition.
Key Markers:
- Triglycerides: Most sensitive to NNMT inhibition
- LDL cholesterol: Often decreases with metabolic improvement
- HDL cholesterol: May increase as metabolism improves
Testing Schedule: Baseline, 8 weeks, 16 weeks
TriglyceridesTarget: < 80 mg/dL
Optimal
Normal
Borderline
High
LDL CholesterolTarget: < 100 mg/dL
Optimal
Borderline
High
Very High
HDL CholesterolTarget: > 60 mg/dL
Studies show triglycerides are among the first lipid markers to improve with NNMT inhibition. A 2024 study found "decreased circulating cholesterol levels" in mice treated with NNMT inhibitors, with triglycerides showing the most dramatic improvement.
Lab #2: Fasting Insulin — Insulin Sensitivity Marker
Why It Matters: This is the lab most people skip — and the one that reveals if 5-amino-1MQ is working at the cellular level. Fasting insulin improvements often appear 4-6 weeks before noticeable weight loss.
Optimal Range: 2-5 µIU/mL (anything above 10 suggests insulin resistance)
What Research Shows: Studies consistently demonstrate that NNMT inhibition "enhances insulin sensitivity" through NAD+-dependent metabolic pathways. This improvement is measurable weeks before body composition changes.
Testing Schedule: Baseline, 4 weeks, 8 weeks, 12 weeks
Fasting InsulinTarget: 2–5 µIU/mL
Optimal
Normal
Elevated
High
Clinical Insight: If fasting insulin isn't improving by week 6-8, consider dose optimization or assess for interfering factors (stress, sleep, diet quality).
Why It Matters: HbA1c reflects 2-3 months of glucose control, making it ideal for tracking longer-term metabolic improvements from NNMT inhibition. It's less sensitive to daily fluctuations than fasting glucose.
Optimal Range: < 5.0% (5.0-5.4% is acceptable, 5.7%+ indicates problems)
NNMT Connection: Research shows NNMT knockout animals have "markedly enhanced fasting blood glucose levels, glucose tolerance, and insulin sensitivity." 5-amino-1MQ mimics these effects in humans.
Testing Schedule: Baseline, 12 weeks, 24 weeks (due to 3-month reflection period)
HbA1cTarget: < 5.0 %
Optimal
Good
Pre-diabetic
Diabetic
Interpretation: HbA1c improvements typically lag behind fasting insulin changes by 6-8 weeks due to the longer reflection period of this marker.
Lab #4: Liver Enzymes (ALT) — Safety Monitoring
Why It Matters: Liver enzymes are critical safety markers for any compound affecting metabolism. While 5-amino-1MQ research shows liver benefits, individual monitoring remains essential.
Key Markers:
- ALT (Alanine Aminotransferase): Most sensitive liver marker
- AST (Aspartate Aminotransferase): Secondary liver indicator
Safety Thresholds:
- ALT > 3x upper normal limit = stop immediately
- ALT > 2x upper normal = reduce dose and retest in 1 week
- Gradual ALT increase = monitor closely
Research Context: Studies actually show liver improvements with NNMT inhibition. Research indicates NNMT produces 1-MNA, which "promotes hepatotoxicity and abnormal TG storage in the liver." Blocking this pathway may improve liver function.
Lab #5: HOMA-IR — Insulin Resistance Index
Why It Matters: HOMA-IR is calculated from fasting glucose and insulin, providing the most sensitive measure of insulin resistance improvement. This is your "early warning system" for 5-amino-1MQ effectiveness.
Calculation: (Fasting Insulin × Fasting Glucose) ÷ 405
Optimal Range: < 1.0 (anything above 1.9 indicates significant insulin resistance)
Why It's Critical: HOMA-IR often improves 2-4 weeks before other markers change. It's the best early indicator that NNMT inhibition is working at the cellular level.
HOMA-IRTarget: < 1.0
Optimal
Normal
Resistant
High
Clinical Application: Track HOMA-IR every 4 weeks during the first 12 weeks. Lack of improvement by week 8 may indicate need for dose adjustment or investigation of interfering factors.
Why It Matters: The CMP covers kidney function, electrolytes, and additional liver markers. It's essential for safety monitoring and detecting metabolic improvements.
Key Components:
- Creatinine/eGFR: Kidney function (should remain stable)
- Glucose: Daily metabolic function
- Additional liver enzymes: Comprehensive liver assessment
Testing Schedule: Baseline, 4 weeks, 12 weeks, then every 6 months
Safety Focus: Any decline in kidney function warrants immediate evaluation, though research doesn't suggest renal toxicity with NNMT inhibition.
Lab #7: Complete Blood Count — Safety Screen
Why It Matters: CBC monitors for any hematologic effects, though research doesn't suggest blood cell impacts with NNMT inhibition. It's included for comprehensive safety monitoring.
Key Markers:
- White blood cell count
- Red blood cell parameters
- Platelet count
Testing Schedule: Baseline, 8 weeks, then every 6 months
Red Flags: Significant changes in any blood cell parameters warrant investigation, though they're not expected with 5-amino-1MQ use.
Lab #8: Inflammatory Markers (Optional)
Why Consider: Some research suggests NNMT inhibition may reduce inflammation through improved cellular metabolism. These markers help track this potential benefit.
Recommended Markers:
- hs-CRP: Most cost-effective inflammation marker
- ESR: Alternative inflammatory indicator
Testing Schedule: Baseline, 12 weeks (optional)
Research Context: Improved cellular NAD+ levels may reduce oxidative stress and inflammatory signaling, though human research is limited.
Testing Schedule: Complete Timeline
Pre-Treatment (Week -1 to -2)
- Complete baseline panel
- Review results before starting
- Identify any contraindications
Early Monitoring (Week 4)
- Fasting insulin + glucose (calculate HOMA-IR)
- Liver enzymes (ALT/AST)
- Basic metabolic panel
Mid-Treatment (Week 8)
- Complete metabolic panel
- Lipid panel
- Fasting insulin + glucose
- CBC
Full Assessment (Week 12)
- Comprehensive recheck of all baseline markers
- HbA1c (first meaningful change)
- Consider inflammatory markers
Long-term (Week 24+)
- Every 6 months if continuing treatment
- Annual comprehensive panels
Interpreting Your Results
Early Success Indicators (Week 4-6)
- HOMA-IR decreasing: Insulin sensitivity improving
- Fasting insulin dropping: Metabolic function enhancing
- Stable liver enzymes: No safety concerns
Significant Progress (Week 8-12)
- Triglycerides improving: Lipid metabolism enhancing
- HbA1c trending down: Glucose control improving
- Energy levels rising: Clinical correlation with lab improvements
Concerning Patterns
- Liver enzymes rising: Dose reduction or discontinuation
- No HOMA-IR improvement by week 8: Protocol reassessment needed
- Worsening insulin resistance: Investigate interfering factors
When to Stop: Safety Red Flags
Immediate Discontinuation:
- ALT/AST > 3x upper normal limit
- Severe unexplained fatigue
- Significant kidney function decline
Dose Reduction Warranted:
- ALT 2-3x upper normal limit
- Persistent GI symptoms
- No metabolic improvement by week 12
Reassessment Needed:
- Worsening insulin markers despite compliance
- Unexpected lab abnormalities
- New symptoms concerning for toxicity
FAQ
What bloodwork should I get before starting 5-amino-1MQ?
Get a comprehensive metabolic panel, lipid panel, fasting insulin, HbA1c, and liver enzymes (ALT/AST) at baseline. These markers track both safety and effectiveness of NNMT inhibition.
How often should I test bloodwork on 5-amino-1MQ?
Test at baseline, 4 weeks, and 12 weeks. Check liver enzymes more frequently if you have any history of liver issues. HOMA-IR is the best early indicator of effectiveness.
Which lab shows if 5-amino-1MQ is actually working?
HOMA-IR (calculated from fasting glucose and insulin) is the most sensitive early marker. Improvements in insulin sensitivity often appear weeks before weight loss becomes visible.
References
-
Babula JJ, et al. (2024). Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction. Diabetes Obes Metab. PMID:39161060
-
Neelakantan H, et al. (2018). Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochem Pharmacol. PMID:29155147
-
Hong S, et al. (2015). Nicotinamide N-methyltransferase regulates hepatic nutrient metabolism through Sirt1 protein stabilization. Nat Med. PMID:26168293
-
NNMT: a novel therapeutic target for metabolic syndrome. (2024). Front Pharmacol. PMID:38919254